| Rx0000421 |
Aadi Bioscience, Inc. |
04/14/2025 |
80803015350 |
Fyarro Intravenous Suspension Reconstituted 100 MG 1 vial |
01/01/2025 |
343.57 |
7978.53 |
10/28/2040 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074230630 |
RINVOQ TABLET EXTENDED RELEASE 24 HR 15 mg 30 |
01/02/2025 |
321.56 |
6752.77 |
03/09/2038 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074231030 |
RINVOQ TABLET EXTENDED RELEASE 24 HR 30 mg 30 |
01/02/2025 |
321.56 |
6752.77 |
03/09/2038 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074104328 |
RINVOQ TABLET EXTENDED RELEASE 24 HR 45 mg 28 |
01/02/2025 |
600.24 |
12605.04 |
03/09/2038 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074106501 |
SKYRIZI ON-BODY WEARABLE INJECTOR 180 mg/1.2 mL (150 mg/mL) 1.2 |
01/02/2025 |
1366.13 |
22383.49 |
02/04/2034 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074107001 |
SKYRIZI ON-BODY WEARABLE INJECTOR 360 mg/2.4 mL (150 mg/mL) 2.4 |
01/02/2025 |
1366.13 |
22383.49 |
02/04/2034 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074210001 |
SKYRIZI PEN PEN INJECTOR (ML) 150 mg/mL 1 |
01/02/2025 |
1366.13 |
22383.49 |
02/04/2034 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
04/28/2025 |
00074105001 |
SKYRIZI SYRINGE (ML) 150 mg/mL 1 |
01/02/2025 |
1366.13 |
22383.49 |
02/04/2034 |
Single Source Drug |
None |
None |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000513 |
Acertis Pharmaceuticals LLC |
04/25/2025 |
72989040930 |
PHENDIMETRAZINE TARTRATE EXTENDED RELEASE CAPSULES 1 PACK 30 CAPS 105 MG |
03/01/2025 |
8.87 |
98.46 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Acertis' pricing strategy is founded on a comprehensive analysis of various factors, including competitive market dynamics, escalating supply chain and operational expenses, distribution and wholesaler fees, as well as research and development costs. Additionally, pricing decisions are influenced by the limited size of patient populations for certain products. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
04/28/2025 |
66215040201 |
VELETRI® (epoprostenol) Strength:1.5 MG Package Size:1 Form:Vial |
01/28/2025 |
3.13 |
55.26 |
03/15/2027 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025. |
| Rx0000459 |
AltaThera Pharmaceuticals LLC |
01/02/2025 |
69724011210 |
Sotalol hydrochloride - Injection: 10-mL vial containing sotalol hydrochloride 150 mg |
01/01/2025 |
327.00 |
3623.00 |
08/21/2039 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
At AltaThera, we are committed to upholding the highest standards of confidentiality and integrity. We want to emphasize that information related to our unit sales volume and cost increase factors is deemed nonpublic and proprietary. This includes, but is not limited to, detailed sales figures, production costs, and any associated sensitive data. We strictly prohibit the disclosure of such information to external parties without explicit authorization. This commitment is integral to maintaining a competitive edge in the market and safeguarding our business interests. |
| Rx0000231 |
American Health Packaging |
04/04/2025 |
68084029121 |
Naltrexone HCl Oral Tablet 50 MG 30 tablets per box |
02/07/2025 |
11.28 |
86.51 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/28/2025 |
00517750425 |
ACETYLCYSTEINE SOLUTION 10%, 100MG/ML, 4ML Vial, PKG OF 25 |
02/01/2025 |
11.75 |
271.25 |
None |
Non-innovator Multiple Source Drug |
None |
None |
14113532 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/28/2025 |
00517760425 |
ACETYLCYSTEINE SOLUTION 20%, 4ML, PKG OF 25 |
02/01/2025 |
15.50 |
361.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
31571001 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/28/2025 |
00517250210 |
Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk |
02/01/2025 |
24.60 |
365.10 |
None |
Non-innovator Multiple Source Drug |
None |
None |
3010067 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/29/2025 |
00517420125 |
HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25 |
02/01/2025 |
31.50 |
731.50 |
None |
Non-innovator Multiple Source Drug |
None |
None |
4160225 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/28/2025 |
00517560125 |
HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25 |
02/01/2025 |
34.75 |
806.50 |
None |
Non-innovator Multiple Source Drug |
None |
None |
7200522 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/29/2025 |
00517930225 |
MULTRYS (TRACE ELEMENTS INJECTION 4, (zinc 1,000 mcg, copper 60 mcg,
manganese 3 mcg, and selenium 6mcg) 1ML Vial ,USP, PKG. OF 25 |
02/01/2025 |
26.75 |
623.00 |
07/01/2041 |
Single Source Drug |
None |
None |
16424382 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
04/29/2025 |
00517930525 |
Tralement (TRACE ELEMENTS INJECTION 4 USP, (Zinc 3 mg, Copper 0.3 mg,
Manganese 55 mcg, Selenium 60mcg), 1ML Vial, PKG. OF 25) |
02/01/2025 |
29.00 |
674.50 |
07/01/2041 |
Single Source Drug |
None |
None |
143985898 |
None |
Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No change or Improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896066930 |
Emverm Oral Tablet Chewable 100 MG |
01/20/2025 |
67.20 |
746.00 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896040201 |
Opicapone 25 MG Capsule 30 EA |
01/20/2025 |
66.36 |
736.71 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896040301 |
Opicapone 50 MG Capsule 30 EA |
01/20/2025 |
66.36 |
736.71 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069701 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100 |
01/20/2025 |
91.22 |
1012.64 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069713 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60 |
01/20/2025 |
54.73 |
607.59 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069801 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100 |
01/20/2025 |
126.50 |
1404.26 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069813 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60 |
01/20/2025 |
75.90 |
842.57 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069901 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100 |
01/20/2025 |
162.68 |
1805.93 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069913 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60 |
01/20/2025 |
97.07 |
1077.62 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896070001 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100 |
01/20/2025 |
232.87 |
2585.09 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896070013 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60 |
01/20/2025 |
139.72 |
1551.07 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896070101 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100 |
01/20/2025 |
303.95 |
3374.18 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896070113 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60 |
01/20/2025 |
182.37 |
2024.51 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069501 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100 |
01/20/2025 |
47.51 |
527.37 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069513 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60 |
01/20/2025 |
28.50 |
316.39 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069601 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100 |
01/20/2025 |
69.36 |
769.96 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
04/11/2025 |
64896069613 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60 |
01/20/2025 |
41.62 |
461.98 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/20/2025 |
62559019016 |
METOCLOPRAMIDE HCL 5 mg/5 mL 473 SOLUTION, ORAL |
02/03/2025 |
35.00 |
70.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Due to market constraints and to avoid any supply disruptions of this important medicine, ANI has invested in increased production and manpower. Along with the increase in production there have been significant labor and material increases over previous years that ANI has absorbed rather than take a price increase. This increase allows ANI to continue to manufacture this product sustainably at this time. |
None |
There was no change or improvement to the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
60631004030 |
EDARBI (azilsartan medoxomil) , 30 tablets , 40 mg |
01/01/2025 |
21.39 |
259.09 |
03/26/2028 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
60631008030 |
EDARBI (azilsartan medoxomil) , 30 tablets , 80 mg |
01/01/2025 |
23.25 |
281.62 |
03/26/2028 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
60631041230 |
EDARBYCLOR (azilsartan medoxomil / chlorthalidone) , 30 tablets , 40 mg / 12.5 mg |
01/01/2025 |
21.95 |
265.81 |
07/01/2031 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
60631042530 |
EDARBYCLOR (azilsartan medoxomil / chlorthalidone) , 30 tablets , 40 mg / 25 mg |
01/01/2025 |
21.95 |
265.81 |
07/01/2031 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
53451010301 |
HORIZANT (gabapentin enacarbil) extended-release tablet , 30 tablets , 300 mg |
01/01/2025 |
46.41 |
562.11 |
06/10/2029 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
04/29/2025 |
53451010101 |
HORIZANT (gabapentin enacarbil) extended-release tablet , 30 tablets , 600 mg |
01/01/2025 |
46.41 |
562.11 |
06/10/2029 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877045860 |
Capecitabine Tablets 150MG 60 Count Bottle |
02/09/2025 |
5.13 |
35.75 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877077258 |
Diclofenac Potassium Powder for solution 9 50MG Packets |
02/09/2025 |
128.75 |
478.81 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012420 |
Silver sulfadiazine cream 1% 20gm tube |
03/24/2025 |
3.30 |
9.15 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012425 |
Silver sulfadiazine cream 1% 25gm tube |
03/24/2025 |
3.70 |
11.15 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012440 |
Silver sulfadiazine cream 1% 400gm jar |
03/24/2025 |
14.50 |
67.25 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012450 |
Silver sulfadiazine cream 1% 50gm jar |
03/24/2025 |
4.70 |
16.95 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012405 |
Silver sulfadiazine cream 1% 50gm tube |
03/24/2025 |
4.70 |
16.95 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000141 |
Ascend Laboratories, LLC |
04/23/2025 |
67877012485 |
Silver sulfadiazine cream 1% 85gm tube |
03/24/2025 |
4.45 |
26.50 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
No Change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
04/23/2025 |
00310066812 |
Lynparza TAB 100MG 120 Count Bottle |
01/01/2025 |
505.63 |
17360.06 |
10/25/2041 |
Single Source Drug |
None |
None |
1713263269 |
None |
When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
No changes to report, product launched on 08/17/2017 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand |
| Rx0000015 |
AstraZeneca |
04/23/2025 |
00310066860 |
Lynparza TAB 100MG 60 Count Bottle |
01/01/2025 |
252.82 |
8680.03 |
10/25/2041 |
Single Source Drug |
None |
None |
1713263269 |
None |
When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
No changes to report, product launched on 08/17/2017 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand |
| Rx0000015 |
AstraZeneca |
04/23/2025 |
00310067912 |
Lynparza TAB 150MG 120 Count Bottle |
01/01/2025 |
505.63 |
17360.06 |
10/25/2041 |
Single Source Drug |
None |
None |
1713263269 |
None |
When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
No changes to report, product launched on 08/17/2017 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand |
| Rx0000015 |
AstraZeneca |
04/23/2025 |
00310067960 |
Lynparza TAB 150MG 60 Count Bottle |
01/01/2025 |
252.82 |
8680.03 |
10/25/2041 |
Single Source Drug |
None |
None |
1713263269 |
None |
When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. |
None |
No changes to report, product launched on 08/17/2017 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand |
| Rx0000354 |
AVEO Pharmaceuticals, Inc. |
04/29/2025 |
45629008901 |
Fotivda Oral Capsule 0.89 mg, 21 count bottle |
01/27/2025 |
1514.00 |
31796.00 |
11/05/2039 |
Single Source Drug |
None |
None |
None |
1 |
The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, and overall research and development costs. |
None |
No change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039.
Patent Data for Tivozanib [sourced from: FDA Orange Book]
Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE
Product No.: 001
Patent No.: 6821987
Patent Expiration: 04/26/2025
Drug Substance: DS
Drug Product: DP
Patent Use Code: U-3100
Delist Requested:
Submission Date: 04/06/2021
Product No.: 001
Patent No: 7166722
Patent Expiration: 11/16/2028
Drug Substance: DS
Drug Product: DP
Patent Use Code:
Delist Requested:
Submission Date: 04/06/2021
Product No.: 001
Patent No.: 11504365
Patent Expiration: 11/05/2039
Drug Substance:
Drug Product:
Patent Use Code: U-3476
Submission Date: 12/01/2022
U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS
Exclusivity Data
Product No.: 001
Exclusivity Code: NCE
Exclusivity Expiration: 03/10/2026 |
| Rx0000354 |
AVEO Pharmaceuticals, Inc. |
04/29/2025 |
45629013401 |
Fotivda Oral Capsule 1.34 mg, 21 count bottle |
01/27/2025 |
1514.00 |
31796.00 |
11/05/2039 |
Single Source Drug |
None |
None |
None |
1 |
The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, and overall research and development costs. |
None |
No change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039.
Patent Data for Tivozanib [sourced from: FDA Orange Book]
Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE
Product No.: 001
Patent No.: 6821987
Patent Expiration: 04/26/2025
Drug Substance: DS
Drug Product: DP
Patent Use Code: U-3100
Delist Requested:
Submission Date: 04/06/2021
Product No.: 001
Patent No: 7166722
Patent Expiration: 11/16/2028
Drug Substance: DS
Drug Product: DP
Patent Use Code:
Delist Requested:
Submission Date: 04/06/2021
Product No.: 001
Patent No.: 11504365
Patent Expiration: 11/05/2039
Drug Substance:
Drug Product:
Patent Use Code: U-3476
Submission Date: 12/01/2022
U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS
Exclusivity Data
Product No.: 001
Exclusivity Code: NCE
Exclusivity Expiration: 03/10/2026 |
| Rx0000108 |
AvKare |
04/30/2025 |
42291045590 |
Eplerenone 50mg Tablet 90ct |
02/19/2025 |
39.49 |
73.42 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000108 |
AvKare |
04/30/2025 |
42291052201 |
Propranolol HCl ER 60mg Capsule 100ct |
01/24/2025 |
6.07 |
41.24 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000108 |
AvKare |
04/30/2025 |
42291052301 |
Propranolol HCl ER 80mg Capsule 100ct |
01/24/2025 |
6.61 |
47.80 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000108 |
AvKare |
04/30/2025 |
50268087228 |
Urea Cream 40% 1oz (28.35 grams) 1 tube |
01/29/2025 |
8.91 |
43.31 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000580 |
Avyxa Pharma, LLC |
04/22/2025 |
83831013401 |
Lutrate Depot (Leuprolide acetate for depot suspension) Injection 22.5 mg, 1 kit |
03/26/2025 |
644.93 |
2000.00 |
None |
Single Source Drug |
None |
None |
None |
1 |
Avyxa has recently acquired Lutrate Depot (leuprolide acetate for depot suspension), which is a gonadotropin-releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer. This product utilizes a microsphere drug delivery which is made out of biodegradable polymers that are known to pose no threat to the body and can hold a diverse array of drugs that can be delivered to the patient through a simple injection. Microspheres are historically known for being challenging and costly to manufacture. Avyxa is committed to providing education materials to both health care professional and patients through the use of professional sales staff and will be establishing co-pay assistance programs for eligible patients. |
None |
No change or improvement necessitates the price increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000429 |
Axsome Therapeutics, Inc. |
04/09/2025 |
81968035101 |
Sunosi - Tablet - 150mg - 30 |
01/01/2025 |
52.33 |
924.66 |
12/30/2042 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
05/09/2022 |
Jazz Pharmaceuticals |
53000000 |
None |
Axsome aquired Sunosi with a total upfront payment of $53 million a high single-digit royalty on Axsome's U.S. net sales of Sunosi in the current indication and a mid single-digit royalty on Axsome's U.S. net sales of Sunosi in future indications. |
755.00 |
755.00 |
2019 |
660.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations. All information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore Gross Sales Volume US Dollars Cost Increase Factors and Change Improvement Description have been left blank. |
| Rx0000429 |
Axsome Therapeutics, Inc. |
04/09/2025 |
81968035001 |
Sunosi - Tablet - 75mg - 30 |
01/01/2025 |
52.33 |
924.66 |
12/30/2042 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
05/09/2022 |
Jazz Pharmaceuticals |
53000000 |
None |
Axsome aquired Sunosi with a total upfront payment of $53 million a high single-digit royalty on Axsome's U.S. net sales of Sunosi in the current indication and a mid single-digit royalty on Axsome's U.S. net sales of Sunosi in future indications. |
755.00 |
755.00 |
2019 |
660.00 |
None |
The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations. All information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore Gross Sales Volume US Dollars Cost Increase Factors and Change Improvement Description have been left blank. |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652400101 |
EPANED (enalapril maleate) Oral Solution , 150 mL , 1 mg / mL |
01/01/2025 |
56.06 |
678.93 |
03/25/2036 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652900103 |
EPRONTIA (topiramate) Oral Solution , 120 mL , 25 mg / mL |
01/01/2025 |
27.56 |
333.74 |
08/21/2040 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652900102 |
EPRONTIA (topiramate) Oral Solution , 240 mL , 25 mg / mL |
01/01/2025 |
51.44 |
622.97 |
08/21/2040 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
65628020405 |
FIRVANQ (vancomycin) Oral Solution , 150 mL , 25 mg / 5 mL |
01/01/2025 |
11.10 |
134.44 |
03/13/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
65628020605 |
FIRVANQ (vancomycin) Oral Solution , 150 mL , 50 mg / 5 mL |
01/01/2025 |
14.70 |
178.05 |
03/13/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
65628020510 |
FIRVANQ (vancomycin) Oral Solution , 300 mL , 25 mg / 5 mL |
01/01/2025 |
15.00 |
181.65 |
03/13/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
65628020810 |
FIRVANQ (vancomycin) Oral Solution , 300 mL , 50 mg / 5 mL |
01/01/2025 |
23.41 |
283.54 |
03/13/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652600101 |
FLEQSUVY (baclofen) Oral Suspension , 120 mL , 5 mg / mL |
01/01/2025 |
65.34 |
791.33 |
09/29/2037 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338005008 |
GLIADEL Sterile Wafers (carmustine implant) , 8 Wafers , 192.3 mg; 7.7 mg |
01/01/2025 |
3487.70 |
42239.96 |
None |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338023030 |
NYMALIZE (nimodipine) ENFit PRE-FILLED ORAL SYRINGE , 12 x 5 mL , 30 mg / 5 mL |
01/01/2025 |
52.92 |
640.95 |
04/16/2038 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338026008 |
NYMALIZE (nimodipine) oral solution , 237 mL , 60 mg / 10 mL |
01/01/2025 |
214.57 |
2598.64 |
04/16/2038 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338026012 |
NYMALIZE (nimodipine) PRE-FILLED ORAL SYRINGE , 12 x 10 mL , 60 mg / 10 mL |
01/01/2025 |
105.85 |
1281.95 |
04/16/2038 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338023012 |
NYMALIZE (nimodipine) PRE-FILLED ORAL SYRINGE, 30 mg / 5 mL, 12 x 5 mL |
01/01/2025 |
52.92 |
640.95 |
04/16/2038 |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652300101 |
QBRELIS (lisinopril) Oral Solution , 150 mL , 1 mg / mL |
01/01/2025 |
56.38 |
682.78 |
11/06/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338053025 |
SOTYLIZE (sotalol hydrochloride) oral solution , 250 mL , 5 mg / mL |
01/01/2025 |
48.55 |
588.04 |
08/31/2035 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338053048 |
SOTYLIZE (sotalol hydrochloride) oral solution , 480 mL , 5 mg / mL |
01/01/2025 |
93.23 |
1129.07 |
08/31/2035 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652195002 |
THYQUIDITY (levothyroxine sodium) Oral Solution , 2 x 100 mL , 100 mcg / 5 mL |
01/01/2025 |
23.85 |
288.80 |
08/06/2031 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338015020 |
TRIPTODUR (triptorelin) for extended release injectable suspension , 1 Unit , 22.5 mg |
01/01/2025 |
1841.09 |
22297.67 |
06/30/2029 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652200101 |
Xatmep (methotrexate) Oral Solution , 120 mL , 2.5 mg / mL |
01/01/2025 |
206.45 |
2500.39 |
01/02/2033 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652200106 |
Xatmep (methotrexate) Oral Solution , 60 mL , 2.5 mg / mL |
01/01/2025 |
108.45 |
1313.49 |
01/02/2033 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085303 |
ZENZEDI 10mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 10 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085403 |
ZENZEDI 15mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 15 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085003 |
ZENZEDI 2.5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 2.5 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085503 |
ZENZEDI 20mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 20 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085603 |
ZENZEDI 30mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 30 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085103 |
ZENZEDI 5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 5 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
24338085203 |
ZENZEDI 7.5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 7.5 mg |
01/01/2025 |
27.29 |
330.52 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000430 |
Azurity Pharmaceuticals |
04/29/2025 |
52652800101 |
ZONISADE (zonisamide) Oral Suspension , 150 mL , 100 mg / 5 mL |
01/01/2025 |
34.64 |
419.55 |
08/18/2038 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |